Vaxcyte Inc (PCVX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Vaxcyte Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 54.10 $ — 73% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 0.0% failed
- Share count grows by less than 3% a year 28.0% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 1,332 m net cash passed
- Operating cash flow covers the profits of the last three years 228 m failed
- Return on capital at 15% or higher, or up versus two years ago -32.5% failed
- Insiders hold at least 10% or are net buyers 0.5% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 101.5% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 10
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -8.48 | -9.81 – -6.22 | 0 | -50.7% | 7 |
| 12/31/2027 | -7.42 | -11.47 – -5.42 | 87 | 12.5% | 7 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -1.47 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.12 | – | 0 | -100.00 | – | -111 | -141 |
| 2025: Q1 | -1.04 | – | 0 | – | – | -166 | -193 |
| 2025: Q2 | -1.22 | – | 0 | – | – | -121 | -102 |
| 2025: Q3 | -1.56 | – | 0 | – | – | -143 | -155 |
| 2025: Q4 | -1.81 | – | 0 | – | – | -225 | -219 |
| 2026: Q1 | -2.30 | – | 0 | – | – | -281 | -295 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | – | -18 | -17 | -4.83 | 0 | 31 | 40 |
| 2018 | 0 | -36 | -29 | -1.15 | -30 | -58 | 71 |
| 2019 | 0 | -54 | -50 | -1.03 | -47 | -106 | 66 |
| 2020 | 0 | -90 | -89 | -3.02 | -47 | 346 | 393 |
| 2021 | 0 | -104 | -100 | -1.93 | -121 | 284 | 324 |
| 2022 | 0 | -232 | -223 | -3.44 | -171 | 954 | 1,006 |
| 2023 | 0 | -468 | -402 | -4.14 | -297 | 1,240 | 1,408 |
| 2024 | 0 | -570 | -464 | -3.80 | -453 | 3,306 | 3,511 |
| 2025 | 0 | -924 | -767 | -5.63 | -656 | 2,686 | 3,046 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Vaxcyte, Inc., ein Impfstoff-Innovationsunternehmen im klinischen Stadium, entwickelt Konjugat- und neuartige Proteinimpfstoffe zur Vorbeugung oder Behandlung bakterieller Infektionskrankheiten.
| Employees | 507 |
|---|---|
| Headquarters | San Carlos, CA |
| Address | 825 Industrial Road, 94070 San Carlos, United States |
| Phone | 650 837 0111 |
| Website | vaxcyte.com |
| IPO Date | 12. Jun 2020 |
| ISIN | US92243G1085 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Grant E. Pickering M.B.A. | Co-Founder, CEO & Director | 1968 |
| Andrew L. Guggenhime M.B.A. | President & CFO | 1968 |
| James T. Wassil M.B.A., M.S. | Executive VP & COO | 1969 |
| Mikhail Eydelman J.D. | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 1982 |
| Harp Dhaliwal M.B.A. | Chief Technical Operations Officer | 1973 |
| Jeff Fairman Ph.D. | Co-Founder & VP of Research | 1964 |
| Elvia Cowan | Senior VP of Finance & Chief Accounting Officer | 1973 |
| Jeff Macdonald | Executive Director of Investor Relations | – |
| Whitney Jones | Chief People Officer | – |
| Janet Graesser | Senior Vice President of Corporate Affairs | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 27. Jul 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER | Sell | 378 | 55.91 | 21,135 |
| 27. Jul 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER | Sell | 622 | 55.54 | 34,546 |
| 27. Jul 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER | Sell | 244 | 55.96 | 13,655 |
| 27. Jul 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER | Sell | 756 | 55.52 | 41,970 |
| 27. Jul 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER | Sell | 4,415 | 55.93 | 246,935 |
| 27. Jul 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER | Sell | 11,783 | 55.52 | 654,133 |
| 27. Jul 2026 | Pickering Grant | CHIEF EXECUTIVE OFFICER | Other | 16,198 | 2.03 | 32,882 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.